Dupixent is a dupilumab biologic injection with several qualified US indications. Atopic dermatitis is a major use, but age, body weight, diagnosis and the supplied device determine which instructions apply.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | dupilumab |
| Medicine class | Interleukin-4 receptor alpha antagonist monoclonal antibody |
| Forms and strengths | Subcutaneous injection in the cited label: 200 mg/1.14 mL or 300 mg/2 mL single-dose prefilled syringe or pen; device-age restrictions apply |
Atopic dermatitis and the broader label
For atopic dermatitis, the US label covers patients from 6 months with moderate-to-severe disease inadequately controlled by topical prescription therapies or when those are inadvisable. Other qualified indications include asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis, eosinophilic COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis. Age and disease criteria differ substantially.
Source: [1]
A presentation is not a universal regimen
The cited label lists 200 mg/1.14 mL and 300 mg/2 mL syringes and pens. Syringes can be used from 6 months, while pens are for ages 2 and older under the cited instructions. Diagnosis, age and weight affect loading and maintenance plans. Children require the specified caregiver administration or supervision.
Source: [1]
Eye and other symptoms to report
Conjunctivitis, keratitis and blepharitis are labeled concerns. Report new or worsening eye symptoms promptly, especially persistent pain or visual changes. The label also addresses hypersensitivity, eosinophilic conditions, psoriasis and joint symptoms. Severe allergy requires urgent care; a new symptom should be assessed rather than presumed to be the underlying skin condition.
Source: [1]
Vaccines, parasites and corticosteroid changes
Review vaccinations before starting and avoid live vaccines during treatment under the label's advice. Pre-existing helminth infection should be treated. Do not abruptly stop systemic, inhaled or topical corticosteroids when starting Dupixent; any reduction needs clinical supervision. Dupixent is not a treatment for acute bronchospasm or an asthma emergency.
Source: [1]
Match every indication to its own instructions
An atopic-dermatitis plan should not be applied automatically to eosinophilic esophagitis, COPD or another indication. Some uses require add-on therapy or prior-treatment qualifications. Keep the exact presentation, condition and schedule on the medicine list. Comparison with another dermatitis biologic does not establish interchangeability or extend its approved uses.
For related product context, see the Dupixent and Adbry comparison; treatment changes still require a prescribing review.
Source: [1]
Questions and answers
Do all Dupixent indications start at the same age?
No. The minimum age and other criteria vary by condition; the atopic-dermatitis threshold must not be applied to every use.
Can the Dupixent pen be used at every syringe-approved age?
No. The cited instructions distinguish pens from syringes, including the pen's age-2 threshold.
Can steroids be stopped as soon as Dupixent begins?
No. The label advises against abrupt corticosteroid withdrawal; any reduction must be clinician-led.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026